Promoted Content Promoted Content


Find Clinical Drug Development Pipelines & Deals | PipelineProspector


All Data

Filters Filter refresh
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TG01

            Therapeutic Area: Oncology Product Name: TG01

            Highest Development Status: IND Enabling Product Type: Vaccine

            Partner/Sponsor/Collaborator: IOVaxis Therapeutics

            Deal Size: $3.0 million Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 06, 2021


            Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.